Captopril, Tablet | ||||
CAS NO.: | 62571-86-2 | |||
Chemical Formula: | C9H15NO3S | |||
Molecular Weight: | 217.2900 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Mechanism of Action
The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously administered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and norepinephrine, indicating specificity of action. ACE is identical to "bradykininase", and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. Increased concentrations of bradykinin or prostaglandin E2 may also have a role in the therapeutic effect of Captopril. Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity (PRA), the latter resulting from loss of negative feedback on renin release caused by reduction in angiotensin II. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along with sodium and fluid loss. The antihypertensive effects persist for a longer period of time than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular endothelium is inhibited longer than the ACE in circulating blood. **Please noted, we do not sell medicines to Individuals. Our products are for Pharmaceutical Companies, Wholesalers, Research Organization and Institutes. A safe online Medicine store should have License by the state board of pharmacy, have a licensed pharmacist, require a prescription and more. For instructions about how to purchase the medicines online, please review FDA official website. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
CAPTOPRIL | TABLET;ORAL | Please contact us for more details | Please contact us for more details | Please contact us for more details |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
N.A. | N.A. | N.A. | N.A. | N.A. |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
N.A. | N.A. | |||